Collaboration and education are critical to understanding and managing this mounting public health problem
Drug‐induced liver injury (DILI) is a major cause of acute liver failure, leading to liver transplantation and death,1 and it is one of the most frequent safety‐related causes of drug marketing withdrawals.2 DILI poses a growing challenge for clinicians, researchers, and regulatory bodies, with a vast array of new medications and herbal and dietary supplements constantly becoming available. Despite decades of experience with drug hepatotoxicity and the relatively recent development of clinical guidelines, registries, and other collaborative resources, much is still to be learned in this important field of medicine.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplant 2004; 10: 1018–1023.
- 2. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry. Drug‐induced liver injury: premarketing clinical evaluation. July 2009. https://www.fda.gov/media/116737/download (viewed June 2021).
- 3. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145–155.
- 4. Nash E, Sabih AH, Chetwood J, et al. Drug‐induced liver injury in Australia, 2009–2020: the increasing proportion of non‐paracetamol cases linked with herbal and dietary supplements. Med J Aust 2021; 215: 261–268.
- 5. Barnes J, McLachlan AJ, Sherwin CM, Enioutina EY. Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand. Expert Rev Clin Pharmacol 2016; 9: 905–915.
- 6. Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology 2017; 65: 363–373.
- 7. Luber RP, Rentsch C, Lontos S, et al. Turmeric induced liver injury: a report of two cases. Case Reports Hepatol 2019; 2019: 1–4.
- 8. Therapeutic Goods Administration. An overview of the regulation of complementary medicines in Australia. Mar 2013. https://www.tga.gov.au/overview‐regulation‐complementary‐medicines‐australia (viewed June 2021).
- 9. Benesic A, Leitl A, Gerbes AL. Monocyte‐derived hepatocyte‐like cells for causality assessment of idiosyncratic drug‐induced liver injury. Gut 2016; 65: 1555.
- 10. Fontana RJ, Watkins PB, Bonkovsky HL, et al; DILIN Study Group. Drug‐Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Safety 2009; 32: 55–68.
- 11. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and research information on drug‐induced liver injury. Bethesda (MD): NIDDKD, 2012 (updated June 2021). https://www.ncbi.nlm.nih.gov/books/NBK547852 (viewed June 2021).
- 12. Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 2009; 5: 463–473.
No relevant disclosures.